Overview

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of the investigational drug in combination with radiation to learn whether the drug(s) works in treating a specific disease. In this study, researchers are studying three treatment arms, each using standard chemotherapy, with the drug cisplatin and radiation and the drug Nivolumab. Each treatment Arm will test the addition of Nivolumab at a different time point

Phase:

Phase 2

Details

Lead Sponsor:

Don Dizon

Collaborators:

Bristol-Myers Squibb
Rhode Island Hospital
The Miriam Hospital
Women and Infants Hospital of Rhode Island

Treatments:

Antibodies, Monoclonal
Cisplatin
Nivolumab